Browse the evidence

GLP-1 receptor agonists reduced major adverse cardiovascular events (MACE) by 31% in Asians.

GLP-1RAs may provide significant cardiovascular benefits for Asian populations.

Tirzepatide produced meaningful weight loss across groups, but outcomes varied based on weight-reduction status and T2D status.

Practitioners should consider individual patient factors when prescribing tirzepatide for weight loss.

GLP-1/dual agonists were associated with a 54% lower incidence of physician-reported sleep apnea (PRSA).

Practitioners may consider GLP-1/dual agonists as a treatment option to reduce the incidence of sleep apnea in patients with obesity and type 2 diabetes.

Liraglutide, dulaglutide, semaglutide, and tirzepatide individually reduced the incidence of PRSA compared to the reference arm.

Each GLP-1/dual agonist may be effective in reducing sleep apnea incidence, offering multiple treatment options.

There was a 79% lower incidence of positive airway pressure reports in the GLP-1/dual agonist group compared to controls.

The use of GLP-1/dual agonists may lead to fewer patients requiring positive airway pressure therapy.

Glucose-dependent insulinotropic polypeptide (GIP) acts as a bifunctional blood sugar stabilizing factor in type 2 diabetes.

GIP may be considered in therapeutic strategies for managing blood sugar in type 2 diabetes.

The dual stimulation of the GIP and GLP1 receptor may provide benefits in treating type 2 diabetes and obesity.

Consider dual receptor agonists in treatment plans for better outcomes in diabetes and obesity.

The S3 guideline for the prevention and treatment of obesity includes new recommendations on stigmatization, diagnostics, and therapy, incorporating areas like E-Health.

Practitioners should consider the new recommendations in their approach to obesity treatment.

GLP-1 receptor (GLP-1R) agonists significantly reduce the occurrence of major adverse cardiovascular events in individuals with type 2 diabetes (T2D).

Practitioners should consider GLP-1R agonists as a therapeutic option for reducing cardiovascular risks in T2D patients.

Cricket protein ingestion results in higher postprandial blood amino acid concentration compared to beef protein.

Insect protein may be more effective than some traditional animal proteins for amino acid delivery.

There is no difference in skeletal muscle anabolism between insect and animal protein sources.

Both insect and animal proteins can be used interchangeably for muscle building.

Incretin-based glucose-lowering medications, including DPP-4 inhibitors and GLP-1 receptor agonists, open new perspectives in the treatment of type 2 diabetes.

Practitioners should consider incretin-based therapies as viable options for managing type 2 diabetes.

The dual receptor agonist tirzepatide has been approved for clinical use by the FDA.

Healthcare providers can now prescribe tirzepatide as part of diabetes management.

The treatment of obesity is undergoing significant changes due to new weight-reducing medications, innovations in intervention, digital therapy options, and political decisions.

Practitioners should be aware of the evolving landscape of obesity treatment options.

Glucagon-like peptide 1 receptor agonists hold great promise to reverse some cancer risk in people living with obesity.

GLP-1 receptor agonists may be considered in obesity management to potentially reduce cancer risk.

Endoluminal bariatric and metabolic therapies have expanded significantly, with FDA-approved therapies available for patients with a body mass index as high as 50 kg/m².

Practitioners should consider these therapies for patients with high BMI who may not qualify for traditional bariatric surgery.

Obesity management requires understanding both genetic and environmental components.

Practitioners should consider both genetic and lifestyle factors in obesity treatment.

Lifestyle interventions can help in the prevention and treatment of obesity by altering epigenetic signatures.

Encouraging lifestyle changes can be an effective strategy in obesity treatment.

There are no significant differences in muscle mass and strength gains between consuming protein three or five times a day.

Practitioners can advise that both three and five protein meals are effective for muscle gain.

Adherence to recommended dosage and seeking medical advice regarding possible side effects/interactions is recommended.

Practitioners should advise patients to follow dosage guidelines and consult healthcare providers.

Liraglutide reduced global eating disorder risk scores.

Practitioners may consider liraglutide as a treatment option for reducing eating disorder risk in patients with obesity or Type 2 diabetes.

Food cravings improved or remained unchanged following liraglutide and semaglutide treatment.

Practitioners should be aware that while some patients may experience reduced cravings, others may not see changes.

PAP+semaglutide was associated with lower incident pulmonary hypertension (PH) at 1 year (RR:0.45) and at 3 years (RR:0.50), and lower mortality at 1 year (RR:0.35) and 3 years (RR:0.37).

Incorporating GLP-1 receptor agonists like semaglutide may enhance treatment outcomes for obese patients with OSA on PAP.

Maximum strength increased marginally significantly by 4.6 kg during the intervention.

Practitioners can expect modest strength improvements with low-intensity training in this population.